首页> 外文期刊>Clinical lymphoma, myeloma & leukemia >Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor
【24h】

Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor

机译:早期BCR-ABL1减少可预测任何酪氨酸激酶抑制剂治疗的新诊断的慢性粒细胞白血病患者的无事件生存率更高

获取原文
获取原文并翻译 | 示例

摘要

The clinical prognostic factors during treatment are very important in chronic myeloid, leukemia. An early molecular response and the halving time of BCR-ABL1 might be highly predictive of the outcome. A retrospective analysis of a cohort of 50 patients showed the importance of a very early molecular response in identifying subjects with favorable outcomes, using ABLI as the control gene for the analysis.
机译:在慢性粒细胞白血病中,治疗期间的临床预后因素非常重要。 BCR-ABL1的早期分子反应和减半时间可能对结果有很高的预测作用。一项对50名患者的回顾性分析表明,使用ABLI作为分析的对照基因,非常早期的分子反应对于识别预后良好的受试者非常重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号